Sponsored by
This is another one of the highlights from the SNO conference this week. Exciting results in recurrent Glioblastoma. Median overall survival of 12.5 months compared to historic controls of 7.2 months. Another elegant solution - see their website for details! When we get some of these treatments approved and can start combining them, we will see major breakthroughs!